Evogene Ltd. (NASDAQ:EVGN) Short Interest Up 263.7% in February

Evogene Ltd. (NASDAQ:EVGN) was the recipient of a large increase in short interest in February. As of February 13th, there was short interest totaling 272,348 shares, an increase of 263.7% from the January 29th total of 74,880 shares. Based on an average daily trading volume, of 2,291,022 shares, the days-to-cover ratio is presently 0.1 days. Currently, 5.5% of the shares of the company are short sold. Currently, 5.5% of the shares of the company are short sold. Based on an average daily trading volume, of 2,291,022 shares, the days-to-cover ratio is presently 0.1 days.

Evogene Stock Up 4.6%

EVGN stock opened at $0.88 on Thursday. The firm has a market cap of $4.71 million, a PE ratio of -1.75 and a beta of 1.35. The business has a 50 day moving average of $1.02 and a 200-day moving average of $1.15. Evogene has a 12-month low of $0.81 and a 12-month high of $2.42.

Institutional Investors Weigh In On Evogene

Hedge funds have recently made changes to their positions in the business. Citadel Advisors LLC grew its position in Evogene by 169.4% during the third quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 36,206 shares during the period. XTX Topco Ltd purchased a new position in Evogene in the fourth quarter valued at about $25,000. Finally, Jane Street Group LLC boosted its stake in Evogene by 58.0% in the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 12,387 shares during the last quarter. 10.40% of the stock is currently owned by institutional investors.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.